BLOG

HCP

Arshad Khanani, MD: ADVM-022 Insights from OPTIC Trial Cohorts 1-3

After presenting initial data from Cohorts 1 and 2 of the phase 1 OPTIC trial in 2019, Cohort 3 results announced by Adverum Biotechnologies are adding to the excitement around ADVM-022 and the prospect of gene therapy in ophthalmology.